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Abstract
Background: We have identified a series of compounds that inhibit protein synthesis in bacteria. Initial IC50’si n
aminoacylation/translation (A/T) assays ranged from 3 to14 μM. This series of compounds are variations on a
5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ol scaffold (e.g., 4H-pyridopyrimidine).
Methods: Greater than 80 analogs were prepared to investigate the structure-activity relationship (SAR). Structural
modifications included changes in the central ring and substituent modifications in its periphery focusing on the 2-
and 6-positions. An A/T system was used to determine IC50 values for activity of the analogs in biochemical assays.
Minimum inhibitory concentrations (MIC) were determined for each analog against cultures of Enterococcus faecalis,
Moraxella catarrhalis, Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli tolC
mutants and E. coli modified with PMBN.
Results: Modifications to the 2-(pyridin-2-yl) ring resulted in complete inactivation of the compounds. However,
certain modifications at the 6-position resulted in increased antimicrobial potency. The optimized compounds
inhibited the growth of E. faecalis, M. catarrhalis, H. influenzae, S. pneumoniae, S. aureus, E. coli tolC, mutants and E.
coli modified with PMBN with MIC values of 4, ≤ 0.12, 1, 2, 4, 1, 1 μg/ml, respectively. IC50 values in biochemical
assay were reduced to mid-nanomolar range.
Conclusion: 4H-pyridopyrimidine analogs demonstrate broad-spectrum inhibition of bacterial growth and
modification of the compounds establishes SAR.
Keywords: antibiotic, drug discovery, structure-activity relationship (SAR), protein synthesis, inhibitor, Staphylococcus
aureus, Streptococcus pneumoniae
1. Background
Bacterial infections continue to represent a major world-
wide health hazard. Our health care systems are increas-
ingly confronted with drug-resistant hospital and
community-acquired infections [1]. With the recent
emergence of numerous, clinically important, drug-resis-
tant bacteria including Staphylococcus aureus, Streptococ-
cus pneumoniae, Enterococcus faecalis, Mycobacterium
tuberculosis, enhanced-spectrum b-lactamase producing
Escherichia coli and Klebsiella sp.a n dPseudomonas aer-
uginosa, an emergency is becoming apparent. Antibacter-
ials kill bacteria by interfering with processes of cellular
function that are essential for their survival. The majority
of clinically important antibiotics target the ribosome
and protein synthesis in general [2,3] and most of these
are naturally occurring antibiotics or derivatives of natu-
rally occurring antibiotics [4,5].
We have developed an aminoacylation/translation (A/T)
system for screening for inhibitors of protein synthesis
and in high throughput screens (HTS) of focused chemical
compounds we identified a class of selective bacterial pro-
tein synthesis inhibitors, 5,6,7,8-tetrahydropyrido[4,3-d]
pyrimidin-4-ol (e.g., 4H-pyridopyrimidine) [6]. Two com-
pounds, 321525 and 321528 (Figure 1), were found to
exhibit the greatest inhibitory activity in the initial HTS
using the A/T assays and subsequently antibacterial activ-
ity was confirmed against S. pneumoniae, S. aureus,a n dE.
coli tolC mutants. The compounds 321525 and 321528
were retested in the A/T assay and inhibited protein
synthesis with IC50’so f2 . 8a n d1 . 2μM, respectively. Mini-
mum inhibitory concentrations (MIC) were determined
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provided the original work is properly cited.for a panel of bacteria including E. faecalis, Moraxella. cat-
arrhalis, Haemophilus influenzae, S. pneumoniae, S. aur-
eus, E. coli tolC mutants, and E. coli modified with PMBN.
The MIC of 321525 and 321528 against these pathogens
was 32, 0.25, 4, 8, 32, 8, 32, and 128, 2, 8, 32, > 128, 128,
32 μg/ml, respectively [6]. The inhibitory activity of these
two compounds encouraged us to initiate structure-activ-
ity relationship (SAR) studies. Previously, minimum
bactericidal concentration testing of the 4H-pyridopyrimi-
dines initially indicated that the compounds were bacteri-
cidal against H. influenzae, but only bacteriostatic against
S. pneumoniae [6,7]. Also, we previously conducted
macromolecular synthesis (MMS) assays to test com-
pounds to determine if RNA, DNA, or protein synthesis
was inhibited in bacterial cultures. Assays were carried out
in cultures containing the E. coli tolC mutant and also in
cultures of S. aureus. The MMS data for two representa-
tive compounds, REP323219 and REP323370, indicate that
the 4H-pyridopyrimidines are specific inhibitors of protein
synthesis in the cell [6]. We report here the results of an
in-depth SAR study of the inhibitory compound series.
2. Methods and materials
The original hit compounds were from a chemical com-
pound library containing 2100 compounds from Asinex
(Moscow, Russia). All analogs of the original hit com-
pounds were prepared by Asinex. Biochemical analysis
and determination of IC50 values of the original com-
pounds and testing of the analogs were carried out
using the A/T assay as described [6]. Broth microdilu-
tion MIC testing was performed in 96-well microtiter
plates according to Clinical Laboratory Standards Insti-
tute (CLSI; formerly NCCLS) document M7-A6 [8].
MIC values were determined for E. faecalis, M. catar-
rhalis, H. influenzae, S. pneumoniae, S. aureus, E. coli
tolC mutants, and E. coli modified with PMBN. MMS
assays were performed in cultures of E. coli tolC
mutants as described [6,9].
3. Results and discussion
We re-evaluated 321376, 321386, 321388, 321378,
321521, 321522, 321524, 321526, 321527, and 321529
from the initial library obtained from Asinex (Figure 2).
These compounds are similar to 321525 and 321528.
The first four were identical to the original compounds
with the exception that the nitrogen in the 2-pyridin-2-
yl was walked around the pyridine ring to the 3-yl and
4-yl positions (Figure 2). Movement of the nitrogen
resulted in complete loss of inhibitory activity, both bio-
chemical and biological (Table 1). Similarly, in the final
six compounds, the effect of the 3-fluoro- and 3-meth-
oxy-benzyl substitution at the 6-position were tested by
removing or walking around these functional groups on
their parent 6-benzyl group. These initial compounds
also contained 2- and 3-hydroxy substitutions at the 6-
position. In the initial HTS, these compounds exhibited
activity, but fell below the cutoff that defined a hit com-
pound. When these compounds were re-assayed in tri-
p l i c a t et h e ye x h i b i t e ds i m i l a rI C 50 values as the original
two compounds (Table 1). When tested against the
panel of bacteria, these compounds also showed similar
bacterial growth inhibition as 321525 and 321528, with
the exception of 321526 which exhibited little or no
anti-bacterial activity.
To determine how critical the structure of the 2-pyri-
din-2-yl ring was to the activity of the compound ser-
ies, we introduced two moderate changes to 321521
(Figure 3). First, a methyl group was added next to the
nitrogen in the pyridine ring (332052) and second, the
pyridine ring was replaced with a pyrazine ring
(323354) (Figure 3). The compound 323354 reduced
potency tenfold and 332052 completely abolished activ-
ity in the A/T assay. Both compounds lost anti-bacter-
ial activity against all bacteria in the panel, except
against M. catarrhalis where the MIC values increased
120- and 60-fold, respectively. Next, the pyridine ring
at the 2-position was replaced with a furan (332053),
or a thiophene (332057), or a methyl thiazole (323356)
(Figure 3). The furan and methyl thiazole replacements
abolished all biochemical activity in the A/T assay,
while biochemical activity of the thiophene replace-
ment was reduced over 40-fold. Only the methyl thia-
zole replacement exhibited slight antibacterial activity.
More analogs will be required to complete a compre-
hensive study of this part of the compound series, but
from these preliminary results all changes were
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Figure 1 The two most potent compounds coming out of the original A/T HTS.
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pound series.
Fifty-eight new compounds were prepared in which the
phenyl ring at the 6-position of the core structure was
modified (Figure 4). In the instances that the modification
contained a hydroxyl or a carbonyl group (323196,
323197, 323200, 323204, 323206, 323210, 323211, 323213,
323214, 323215, 323217, 323222, 323224, 323225, 323231,
323232, 323236, 323238), the biochemical potency was
maintained or increased; however, in each case the micro-
biological inhibition was lost (Table 1). For example, com-
pound 323200 in which the benzene ring was modified to
a 2-(2-methoxyphenoxy) acetamide, the IC50 was
improved three to sevenfold yet the MIC was above maxi-
mum testing concentrations for the entire panel of bac-
teria. When the phenyl ring contained multiple methyl or
methoxy substitutions (323191, 323202, 323209, 323221,
323223, 323226) an overall increase in the IC50 and MIC
values (decrease in potency) was observed. In the case of
323221, the 3,4,5-trimethoxy substitution abolished both
biochemical and microbiological activities.
Further five-member ring (323195, 323234, 323239) or
six-member ring (323192, 323235) substitutions at the 6-
position decreased the potency with the exception of
compound 323195 in which the benzene ring was
replaced with 1-phenylpyrrolidine. In this case, the activ-
ity was observed to be comparable to the original two
compounds. Next, five member-ring structures were
fused to the benzene ring to form five benzodioxoles
(323199, 323205, 323207, 323227, 323233) and one ben-
zimidazol (323213) (Figure 4). These compounds all
tended to decrease potency of the compound series with
the exception of 323227. When the benzene ring was
replaced with 5-chloro-1,3-benzodioxole in 323227 a
three to sevenfold improvement in the IC50 was observed.
A 4-dimethylamino substitution (323218) to the phe-
nyl ring resulted in a five and tenfold improvement in
the IC50 but an increase was observed in the MIC for all
bacteria tested. When the 4-dimethylamino of 323218
was modified to a 4-dimethylaminomethyl group
(323201) or to a 3-diethylaminomethyl group (323193),
biochemical activity was maintained however all antibac-
terial activity was lost.
The most moderate modification to the benzene ring
at the 6-position was the attachment of one or two
halogens to the ring structure. These changes resulted
in increased potency of the compound series in inhibi-
tion of bacterial growth. However, not all of this set of
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Figure 2 Additional compounds identified in the original compound library.
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Page 3 of 8Table 1 IC50 and MIC values of compounds against pathogenic bacteria
Compound
IC50
(μM)
E. fae*
(μg/ml)
M. cat
(μg/ml)
H. flu
(μg/ml)
S. pneumo
(μg/ml)
S. aureus
(μg/ml)
E. coli tolC
(μg/ml)
E. coli +PMBP
(μg/ml)
321376 > 300 N/D N/D N/D N/D > 128 > 128 N/D
321578 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
321386 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
321388 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
321521 2.4 16 0.5 4 16 128 16 64
321522 2.6 16 1 2 16 128 32 64
321524 2.0 16 1 4 16 128 16 64
321526 3.5 > 128 64 > 128 > 128 > 128 > 128 > 128
321527 1.8 64 2 16 32 > 128 64 > 128
321529 2.6 128 2 8 32 > 128 32 128
323191 > 300 128 4 32 32 > 128 128 64
323192 > 300 128 4 64 32 > 128 128 64
323193 4.1 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323194 3.4 64 1 8 8 64 16 16
323195 1.5 64 2 16 32 64 32 16
323196 1.6 32 128 > 128 > 128 > 128 > 128 > 128
323197 4.4 > 128 16 32 128 > 128 > 128 > 128
323198 2.7 > 128 1 8 16 > 128 32 64
323199 1.1 128 1 16 16 128 32 32
323200 0.4 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323201 2.1 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323202 4.3 32 0.25 4 4 16 8 32
323203 2.0 64 1 8 4 16 8 16
323204 2.1 > 128 64 32 128 > 128 > 128 > 128
323205 > 300 128 4 16 32 > 128 64 64
323206 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323207 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323208 2.7 > 128 4 64 32 > 128 64 64
323209 1.5 > 128 4 64 32 > 128 64 64
323210 3.2 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323211 1.6 > 128 64 > 128 > 128 > 128 > 128 > 128
323212 3.4 128 1 > 128 4 64 8 16
323213 2.4 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323214 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323215 2.1 > 128 128 64 > 128 > 128 > 128 > 128
323216 1.1 32 ≤0.12 2 4 16 8 8
323217 4.8 > 128 32 32 > 128 > 128 > 128 > 128
323218 0.24 > 128 4 16 32 > 128 128 64
323219 3.0 32 ≤0.12 4 4 16 8 16
323220 2.1 32 ≤0.12 2 4 16 8 8
323221 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323222 > 300 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323223 14.7 > 128 4 32 32 > 128 128 64
323224 4.9 > 128 16 8 > 128 > 128 > 128 128
323225 17.1 > 128 2 8 128 > 128 > 128 > 128
323226 8.0 > 128 64 > 128 > 128 > 128 > 128 > 128
323227 0.37 > 128 8 32 64 > 128 64 > 128
323228 0.30 64 0.5 4 8 31 16 16
323229 0.53 64 0.5 8 8 64 16 16
323230 2.0 32 0.5 8 8 32 16 16
323231 5.9 128 128 128 128 > 128 > 128 > 128
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Figure 3 Compounds in which the pyridine ring attached to the central scaffold/core in the 2-position was modified.
Table 1 IC50 and MIC values of compounds against pathogenic bacteria (Continued)
323232 3.2 > 128 8 > 128 > 128 > 128 128 > 128
323233 > 300 128 4 16 32 > 128 64 64
323234 5.8 128 16 128 128 > 128 > 128 64
323235 37.9 > 128 8 64 64 > 128 128 128
323236 7.8 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323237 2.8 64 0.5 4 8 32 8 16
323238 2.1 > 128 16 32 > 128 > 128 > 128 > 128
323239 3.0 64 8 64 > 128 > 128 64 128
323338 64.4 16 ≤0.12 2 4 16 4 8
323339 19.0 64 ≤0.12 8 4 32 2 2
323340 > 300 16 ≤0.12 1 2 4 1 2
323341 41.4 32 ≤0.12 2 4 16 8 16
323342 28.9 32 ≤0.12 2 2 32 4 16
323343 8.24 32 ≤0.12 1 2 8 4 2
323344 11.6 32 ≤0.12 4 2 8 1 4
323345 > 300 > 128 32 64 128 > 128 128 128
323353 1.7 > 128 8 32 128 > 128 128 128
323354 21.6 > 128 16 > 128 > 128 > 128 > 128 > 128
323355 32.1 > 128 4 64 64 128 64 64
323356 > 300 128 8 64 128 > 128 128 > 128
323365 2.27 16 ≤0.12 4 4 8 4 4
323366 2.47 8 ≤0.12 4 2 8 4 2
323367 1.89 4 ≤0.12 1 2 8 2 8
323368 0.47 > 128 > 128 > 128 > 128 > 128 > 128 > 128
323369 2.01 64 4 16 64 128 64 32
323370 0.28 16 ≤0.12 2 4 16 8 8
332052 > 300 > 128 32 > 64 > 128 > 128 > 128 > 128
332053 > 300 > 128 > 128 > 64 > 128 > 128 > 128 > 128
332054 7.4 8 ≤0.12 1 2 4 2 1
332055 16.4 64 32 16 128 > 128 128 64
332057 101 > 128 > 128 > 128 > 128 > 128 > 128 > 128
332058 0.56 16 ≤0.12 0.5 2 16 4 4
*E. faecalis, M. catarrhalis, H. influenzae, S. pneumoniae, S. aureus, E. coli tolC mutants, and E. coli modified with PMBN
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Page 5 of 8compounds improved the IC50 values. When two fluor-
ine atoms (323198, 323228, 323230, and 323237) or one
chlorine atom (323216, 323219, and 323220) were
walked around the phenyl ring at the 6-position on the
core structure, the biochemical potency was maintained
or increased. However, the biochemical potency was
decreased with compounds in which two chlorine atoms
(323339, 323340, 323342, 323343, and 323344) were
walked around the phenyl ring. Compounds containing
a 3-bromobenzene or a 2,3-dibromobenzene at the 6-
position (323341, 323367) also decreased biochemical
potency. Even though a moderate decrease in biochem-
ical potency was observed for a subset of these com-
pounds as a whole they exhibited some of the greatest
increases in potency for inhibiting bacterial growth. The
2,3-dimethoxy-5-chloro substitution in 323203 main-
tained biochemical and enhanced antibacterial potency.
The remaining four compounds (323194, 323208,
323212, and 323229) contained 2-(ethenyloxy)benzene,
2-(ethoxymethyl)-3-(methoxybenzene, 2,3-dimethoxy-4
(prop-2-en-1-yl)benzene and 3-(propan-2-yl ether)ben-
zene at the 6-position, respectively. Variations of alkyl,
alkenyl, alkoxyl, and alkenoxy groups exhibited no
extreme shifts in either the IC50 or MIC values,
although all four were potent compounds.
Next, based on compound 323216 (Figure 4), changes
to the 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ol core
were implemented (Figure 5). Removal of the carbonyl
group from the pyrimidine ring of the core (323355)
resulted in moderate increase of both IC50 and the MIC
values. Attachment of a 3-methyl group onto the tetra-
hydropyrido[4,3-d]pyrimidin (323345) abolished most
biochemical and antibacterial activities, whereas addition
of an 8-methyl group (332054) enhanced antibacterial
activity. Oxidation of the tetrahydropyrido[4,3-d]pyrimi-
din core (332055) resulted in a negative effect on the
activity of the compounds series. Ring enlargement to
tetrahydro-3H-pyrimido[5,4-c]azepin (332058) had pro-
found effects on both IC50 and MIC values. The IC50
was improved to 0.56 μM and the MIC values deter-
mined for different bacteria in the panel were improved
to the lowest levels observed for any compound tested.
Finally, changes were made in the linker tethering the
phenyl ring to the 6-position of the core scaffold (Figure
6). First, the point of attachment of the linker was chan-
ged from the 6-position to the 5-position (323338). This
resulted in a significant increase in the IC50 but a slight
improvement in the MIC values. Next, the methylene
linker was replaced with a carbonyl carbon (323353) or
a carboxamido linker (323368). The insertion of the car-
bonyl carbon resulted in decreased potency in bacterial
cultures. The amide group resulted in an improved IC50,
but a complete loss of antibacterial activity was
observed. Next, the length of the carbon linker was
increased by the addition of a carbonyl carbon (323369)
or with an additional carbon (323370). The addition of
the carbonyl carbon significantly increased the MIC.
Insertion of an additional carbon however improved the
IC50 to one of the lowest values recorded and main-
tained low MIC values.
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Figure 4 Compounds in which the benzene ring attached at
the 6-position of the core structure was modified. Asterisk
represents the point of attachment to the core structure.
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Page 6 of 84. Conclusion
In summary, this library of compounds allows a deter-
mination of what kind and where changes in the com-
pound series will be allowed. It is obvious that almost
any change in the pyridine ring at the 2-position of the
core will not be tolerated. Changes to the benzene ring
tethered to the 6-position of the core are permitted but
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Figure 5 Compounds in which the central scaffolds/cores were modified.
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Figure 6 Compounds in which the linker connecting the benzene ring attached at the 6-position of the core structures were modified.
Table 2 Comparison of good IC50 to MIC values
Compound IC50 μM MIC
323218 0.24 +
323227 0.37 +
323228 0.30 ++
323229 0.53 ++
323368 0.47 -
323370 0.28 +++
332058 0.56 +++
+, poor; ++, moderate; +++, good antibacterial activity.
Table 3 Comparison of good MIC to IC50 values
Compound MIC IC50 μM
323338 +++ 64.4
323339 +++ 19.0
323340 +++ > 300
323341 +++ 41.4
323342 +++ 28.9
323343 +++ 8.24
323344 +++ 11.6
323365 +++ 2.27
323366 +++ 2.47
323367 +++ 1.89
323370 +++ 0.28
332054 +++ 7.40
332058 +++ 0.56
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Page 7 of 8tend to increase potency when they are simple in nature.
It is possible to lengthen the 6-linker, but adding func-
tional groups to the linker may impede antibacterial
activity. Of the compounds tested, the IC50 was
improved to sub-micromolar values with seven com-
pounds (Table 2). Most of these compounds maintained
or increased MIC’s when compared to 321525 and
321528; however, one compound completely abolished
antibacterial activity (Table 2). In some instances, there
was a complete disconnect between IC50 and MIC
values. Compound 323340 displayed a good antibacterial
activity; however, it had no inhibitory effect in the A/T
assay suggesting a different mechanism of inhibition
(Table 3). When comparing biochemical inhibitory
activity and antibacterial activity of the compounds, only
two compounds (323370 and 332058) appear in both
tables. It is possible that compounds with good bio-
chemical activity that lack antibacterial potency may not
be able to enter the bacterial cells, or are effluxed or
modified to an inactive state by the bacteria. Also, com-
pounds with good MIC but poor IC50 values may exhi-
bit a secondary mode of action that leads to the
observed antibacterial activity.
We have demonstrated specific inhibition of protein
synthesis in E. coli tolC cells for a number of the com-
pounds described above, including 323202, 323203,
323216, 323219, and 323220. These results indicate that
the types of modifications in these compounds are toler-
ated with regard to maintaining the specific mode of
action. When compared with a known inhibitor (tylosin)
of bacterial protein synthesis, 323219 exhibited similar
inhibition profiles in MMS assays (Figure 7). The other
compounds tested yielded similar results.
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Figure 7 An MMS assay showing inhibition of DNA, RNA, and protein synthesis in E. coli tolC cultures. MMS assays in which (A) 323219
and (B) tylosin were titrated into the assays. In these assays, the IC50 for 323219 and tylosin were calculated to be 6.2 and 11.6 μg/ml,
respectively. Black triangle represents the percent of RNA synthesis, black square represents the percent of DNA synthesis, and black inverted
triangle represents the percent of protein synthesis inhibited.
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